Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773655 · ClinicalTrials.gov registry record
Clinical and Histopathologic Characteristics of BAP1 Mutations
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 196
- Enrollment target
NCT01773655: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01773655 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 196 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01773655 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 196 participants
- Enrollment target
Study Summary
The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen at our institution.
Primary Outcome
Prevalence will be estimated as the proportion of all specimens who tested positive for mutation, and reported along with the corresponding exact 95% confidence intervals.
Interventions
- OTHER tumor specimens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2013-01 |
| Est. Completion | 2020-06-30 |
What the finished NCT01773655 record still lists
NCT01773655 is an observational study that tracks outcomes without assigning an intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which tumor specimens is the first listed.
NCT01773655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01773655 about?
NCT01773655 is a clinical study titled "Clinical and Histopathologic Characteristics of BAP1 Mutations". The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen at our institution.
What is the current status of trial NCT01773655?
This trial is currently completed. The enrollment target is 196 participants. The study started on 2013-01. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT01773655?
The interventions under investigation include: tumor specimens (OTHER).
Who is sponsoring clinical trial NCT01773655?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia